Regeneron Pharmaceuticals announced it won the bankruptcy auction for key assets of 23andMe, according to Benzinga. The $256 million deal aims to expand its genetics-driven drug discovery efforts and is expected to close in the third quarter. The acquisition includes 23andMe’s Personal Genome Service, Total Health, Research Services, Biobank, and infrastructure, with Regeneron pledging no disruption to consumer services. Regeneron committed to maintaining 23andMe’s existing privacy protections, with oversight from a court-appointed Customer Privacy Ombudsman. Co-founder and chief scientific officer George D. Yancopoulos highlighted Regeneron’s commitment to DNA-based drug development.
